Additionally, findings from the FOURIER and ODYSSEY OUTCOMES clinical trials demonstrated a significant reduction in the risk of cerebrovascular disease, encompassing both ischemic stroke and recurrent ischemic stroke, with the utilization of PCSK9 inhibitors. This evidence concerns the gene PCSK9 and cerebrovascular disorder.